BiotechTube
T3D Therapeutics

T3D Therapeutics

Research Triangle Park, United States· Est.
t3dtherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12M

Overview

T3D Therapeutics is pioneering a novel approach to treating Alzheimer's disease by targeting brain 'starvation'—a core metabolic dysfunction characterized by impaired glucose and lipid metabolism. Its lead candidate, T3D-959, is a first-in-class, orally administered dual nuclear receptor agonist that has completed a Phase 2 trial (PIONEER) in mild-to-moderate Alzheimer's patients. The company is positioning itself as a potential disruptor in the neurodegenerative disease space, with a secondary focus on Huntington's Disease, and is actively advancing its clinical program based on recent biomarker and cognitive data presentations.

Alzheimer's DiseaseHuntington's DiseaseNeurodegenerative Diseases

Technology Platform

Small molecule dual nuclear receptor (PPARδ/RXR) agonist platform targeting brain energy metabolism and lipid homeostasis to address neuro-metabolic dysfunction.

Funding History

2
Total raised:$12M
Series A$10M
Grant$2M

Opportunities

The Alzheimer's disease market is vast and lacks safe, oral, disease-modifying treatments.
T3D-959's novel metabolic mechanism addresses a root cause and operates in a less crowded space than amyloid-focused therapies.
Success in AD could enable rapid expansion into other neurodegenerative diseases like Huntington's, where metabolic dysfunction is also a key feature.

Risk Factors

The primary risk is clinical; the novel metabolic hypothesis for Alzheimer's is unproven, and Phase 2 data requires confirmation in larger, pivotal trials.
As a private company, T3D faces significant financial risk in securing the capital needed for expensive late-stage development.
It also faces regulatory and competitive risks in a market now defined by approved anti-amyloid biologics.

Competitive Landscape

T3D competes in the Alzheimer's space dominated by Biogen/Eisai's Leqembi and Lilly's Kisunla, which are anti-amyloid antibodies. Its primary differentiation is an oral, small molecule targeting metabolic dysfunction versus infusion-based antibodies targeting protein aggregates. It also faces competition from other companies exploring metabolic, inflammatory, and tau-based approaches, but its specific PPARδ/RXR mechanism is unique.

More companies in Small Molecule Drugs →More companies in United States →